-
advanced by the
developers of selegiline,
including József
Knoll and Ildikó
Miklya.
Endogenous enhancer substances like
phenethylamine and
tryptamine are known...
- doi:10.1016/S0002-8223(21)04074-8. PMID 3525654. S2CID 902921.
Shimazu S,
Miklya I (May 2004). "Pharmacological
studies with
endogenous enhancer substances:...
-
developers of selegiline,
including József
Knoll and
colleagues like Ildikó
Miklya. PPAP had
previously been
derived by
modification of selegiline. BPAP has...
- (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
Shimazu S,
Miklya I (May 2004). "Pharmacological
studies with
endogenous enhancer substances:...
-
inhibitor similarly to BPAP.]
Yoneda F, Moto T,
Sakae M, Ohde H,
Knoll B,
Miklya I, et al. (May 2001). "Structure-activity
studies leading to...
- Suppl. 136: 44–59. doi:10.1111/j.1600-0404.1991.tb05020.x. PMID 1686954.
Miklya I (November 2016). "The
significance of selegiline/(-)-deprenyl
after 50...
-
stimulation of
which the tryptamine-derived substance, (–)-BPAP, acts.
Gaszner P,
Miklya I (January 2006). "Major
depression and the
synthetic enhancer substances...
-
recombinant enzymes". Drug
Metab Dispos. 29 (11): 1480–1484. PMID 11602525.
Miklya I (November 2016). "The
significance of selegiline/(-)-deprenyl
after 50...
- doi:10.1016/j.conb.2015.01.001. PMC 4508243. PMID 25616211.
Shimazu S,
Miklya I (May 2004). "Pharmacological
studies with
endogenous enhancer substances:...
- (2): 57–66. doi:10.1111/j.1600-0773.1998.tb01399.x. PMID 9498233.
Knoll J,
Miklya I,
Knoll B, Markó R,
Kelemen K (1996). "(-)Deprenyl and (-)1-phenyl-2-propylaminopentane...
